Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.49 |
| ▸ | MEN1 | O00255 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539052 | 0.92 | ALDH1A1 (0.47) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3539797 | 0.88 | ALDH1A1 (0.48) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3535975 | 0.83 | IGF1R (0.46) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3541069 | 0.82 | IGF1R (0.46) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3542743 | 0.82 | ALDH1A1 (0.46) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3541915 | 0.82 | GSK3B (0.42) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL3538022 | 0.82 | IGF1R (0.49) | EGFR | |
| SCHEMBL3542413 | 0.81 | SLC2A1 (0.47) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL1640655 | 0.79 | KMT2A (0.51) | KMT2AMEN1POLBRECQLKDM4E | |
| SCHEMBL3540576 | 0.79 | MEN1 (0.49) | KMT2AMEN1POLBRECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | KMT2A 2866/4885MEN1 3489/4885POLB 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.